12 April 2017

Result of AGM

 

Read more

5 April 2017

[ENCRYPTED]

[ENCRYPTED]

Read more

4 April 2017

1st Patient Dosed in Ph2a Trial for RPL554 in CF

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.

Read more

4 April 2017

Files Statement for Proposed Global Offering

RNS Number : 4464B Verona Pharma PLC 04 April 2017

Read more

4 April 2017

Verona Pharma Doses First Patient in Phase 2a Clinical Trial Evaluating RPL554 for Cystic Fibrosis

Read more

4 April 2017

Verona Pharma Files Registration Statement for Proposed Global Offering

Read more

3 April 2017

Board Change

FOR RNS RELEASE:

Read more

31 March 2017

Appointment of Commercial Director and dry powder formulation development

Read more

31 March 2017

COPD Collaboration and New Commercial Director

Verona Pharma Appoints Richard Hennings as Commercial Director;

Read more

22 March 2017

Services Agreement with QuintilesIMS

Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554

Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us